{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06220214",
            "orgStudyIdInfo": {
                "id": "SBU-BC-NAC-CEDM"
            },
            "secondaryIdInfos": [
                {
                    "id": "IRB2023-00508",
                    "type": "OTHER",
                    "domain": "Stony Brook IRB"
                }
            ],
            "organization": {
                "fullName": "Stony Brook University",
                "class": "OTHER"
            },
            "briefTitle": "Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer",
            "officialTitle": "Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "neoadjuvant-therapy-and-contrast-enhanced-mammography-for-early-stage-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-23",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-05",
            "studyFirstSubmitQcDate": "2024-01-22",
            "studyFirstPostDateStruct": {
                "date": "2024-01-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Alison Stopeck",
                "investigatorTitle": "Professor of Medicine",
                "investigatorAffiliation": "Stony Brook University"
            },
            "leadSponsor": {
                "name": "Alison Stopeck",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant chemotherapy on pathologic complete response rates. The device used to obtain CEDM+CEDBT images is called Siemens MAMMOMAT. This device produces two-dimensional (2D) images, as in a normal mammogram, but also collects additional images for digital breast tomosynthesis (DBT), which produces a three-dimensional (3D) image of the breast in the form of image slices. DBT allows the radiologist to \"see through\" the breast tissue for better detection and localization of breast cancer. By looking at both the CEDM images and the CEDBT images, a radiologist may be able to better detect residual breast cancer in a more cost-effective manner.\n\nParticipation may last up to 18 weeks.\n\nStudy procedures for this research are:\n\n* Undergoing 1-2 mammograms during and/or after your chemotherapy, but before primary breast surgery.\n* Before each mammogram, have a radiology technician inject a liquid contrast agent by inserting a needle into a vein. The chemotherapy port cannot be used to receive the contrast agent\n* Let the research team record information from your medical record related to your condition and the treatment you receive.\n* Give permission to collect leftover tissue from your diagnostic biopsy and breast surgery."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Locally Advanced Breast Cancer",
                "Neoadjuvant Chemotherapy",
                "HER2-positive Breast Cancer",
                "Triple Negative Breast Cancer",
                "TNBC, Triple Negative Breast Cancer"
            ],
            "keywords": [
                "cedm",
                "cedbt",
                "contrast-enhanced digital mammography",
                "contrast-enhanced digital breast tomosynthesis",
                "neoadjuvant chemotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CEDM + CEDBT",
                    "type": "EXPERIMENTAL",
                    "description": "Participants undergo CEDM + CEDBT imaging after every 4-6 cycles of neoadjuvant chemotherapy prior to surgery (imaging may occur up to 2 times)",
                    "interventionNames": [
                        "Diagnostic Test: CEDM",
                        "Diagnostic Test: CEDBT",
                        "Drug: Omnipaque 350mgI/mL Solution for Injection"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "CEDM",
                    "description": "Contrast Enhanced Digital Mammography",
                    "armGroupLabels": [
                        "CEDM + CEDBT"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "CEDBT",
                    "description": "Contrast-Enhanced Digital Breast Tomosynthesis",
                    "armGroupLabels": [
                        "CEDM + CEDBT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Omnipaque 350mgI/mL Solution for Injection",
                    "description": "Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.",
                    "armGroupLabels": [
                        "CEDM + CEDBT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Accuracy of (CEDM+CEDBT) to predict NAC treatment effects",
                    "description": "The ability of CEDM + CEDBT to predict pathologic complete response to neoadjuvant chemotherapy, determined by histopathology evaluation of the resected breast",
                    "timeFrame": "Immediately after definitive breast surgery, up to 24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Accuracy of (CEDM+CEDBT) to detect residual tumor compared with standard of care MRI",
                    "description": "Concordance between CEDM + CEDBT and standard of care MRI in quantifying residual tumor size",
                    "timeFrame": "Immediately before definitive breast surgery"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis with either type of invasive locally advanced breast cancer regardless of hormone receptor or Her2 status\n* Plan to receive at least 4 cycles of neoadjuvant chemotherapy ahead of definitive surgery\n\nExclusion Criteria:\n\n* Pregnancy\n* Allergy/sensitivity to contrast agent\n* Decreased kidney function\n* Diabetes",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alison Stopeck, MD",
                    "role": "CONTACT",
                    "phone": "631-444-7217",
                    "email": "alison.stopeck@stonybrookmedicine.edu"
                },
                {
                    "name": "Caterina Vacchi-Suzzi, PhD",
                    "role": "CONTACT",
                    "phone": "631-216-2993",
                    "email": "caterina.vacchi-suzzi@stonybrookmedicine.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alison Stopeck, MD",
                    "affiliation": "Stony Brook Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stony Brook Breast Center",
                    "status": "RECRUITING",
                    "city": "Stony Brook",
                    "state": "New York",
                    "zip": "11794",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Caterina Vacchi-Suzzi, PhD",
                            "role": "CONTACT",
                            "phone": "631-216-2993",
                            "email": "caterina.vacchi-suzzi@stonybrookmedicine.edu"
                        },
                        {
                            "name": "Hailiang Huang, PhD",
                            "role": "CONTACT",
                            "email": "Hailiang.Huang@stonybrookmedicine.edu"
                        },
                        {
                            "name": "Alison Stopeck, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Wei Zhao",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.92565,
                        "lon": -73.14094
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3152",
                    "name": "Pathologic Complete Response",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}